TC Biopharm (Holdings) Plc (TCBWF)

Market Cap	557.31K
Revenue (ttm)	n/a
Net Income	-15.22M
EPS	-161.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,000
Average Volume	171,639
Open	0.0014
Previous Close	0.0010
Day's Range	0.0014 - 0.0018
52-Week Range	0.0002 - 0.0131
Beta	n/a
RSI	49.18
Earnings Date	Aug 21, 2025

About TC Biopharm (Holdings)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: TCBWF